Analysis of Tumour Tissue Demonstrated Selective Virus Replication
Safety and Efficacy of HSV1716 in Glioma Patients
Sample size: 12
publication
Evidence: low
Author Information
Author(s): H. Jorgensen, E. Allan, S. Graham, L. Richmond, J. Godden, T. Holyoake
Primary Institution: University of Glasgow, Royal Infirmary
Hypothesis
Is HSV1716 injection into the tumor cavity a safe approach for treating glioma?
Conclusion
The study demonstrated that HSV1716 injection into the tumor cavity is a safe approach.
Supporting Evidence
- Two patients with recurrent glioblastoma died due to disease progression.
- Four of the remaining ten patients showed evidence of tumor regrowth.
- Six patients remained well at 7 weeks to 9 months post virus administration.
Takeaway
Doctors injected a virus into brain tumors to see if it was safe, and it turned out to be safe for the patients.
Methodology
Patients with high grade glioma had their tumors surgically resected and HSV1716 injected into tissue adjacent to the cavity.
Limitations
The study had a small sample size and lacked long-term follow-up data.
Participant Demographics
12 patients, including 7 with recurrent disease and 5 newly diagnosed.
Want to read the original?
Access the complete publication on the publisher's website